Rapport Therapeutics (NASDAQ:RAPP) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Rapport Therapeutics (NASDAQ:RAPP) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Several other brokerages have also recently issued reports on RAPP. Raymond James Financial initiated coverage on shares of Rapport Therapeutics in a research report on Friday, April 10th. They set a “strong-buy” rating and a $66.00 target price on the stock. Truist Financial started coverage on Rapport Therapeutics in a research report on Monday, May 18th. They issued a “buy” rating and a $56.00 price target for the company. Citigroup reissued a “market outperform” rating on shares of Rapport Therapeutics in a research note on Tuesday, June 2nd. BTIG Research restated a “buy” rating and set a $65.00 price objective on shares of Rapport Therapeutics in a research report on Wednesday. Finally, William Blair initiated coverage on Rapport Therapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Rapport Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $57.86.

Rapport Therapeutics Stock Performance

RAPP stock opened at $45.49 on Friday. The firm has a fifty day moving average price of $39.77 and a 200 day moving average price of $34.55. Rapport Therapeutics has a fifty-two week low of $13.86 and a fifty-two week high of $48.00. The firm has a market cap of $2.18 billion, a PE ratio of -14.96 and a beta of 0.97.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). On average, equities analysts predict that Rapport Therapeutics will post -4.09 EPS for the current year.

Insider Transactions at Rapport Therapeutics

In related news, major shareholder Rock Ventures V. L.P. Third sold 133,618 shares of Rapport Therapeutics stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $40.24, for a total transaction of $5,376,788.32. Following the completion of the transaction, the insider directly owned 6,299,097 shares of the company’s stock, valued at approximately $253,475,663.28. The trade was a 2.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Abraham Ceesay sold 2,210 shares of the company’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $42.11, for a total transaction of $93,063.10. Following the transaction, the chief executive officer owned 537,607 shares in the company, valued at $22,638,630.77. The trade was a 0.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 154,400 shares of company stock valued at $6,213,660. 12.48% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. AlphaCentric Advisors LLC raised its holdings in shares of Rapport Therapeutics by 6.8% in the first quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock worth $201,000 after buying an additional 408 shares during the period. Russell Investments Group Ltd. boosted its holdings in Rapport Therapeutics by 56.9% during the 4th quarter. Russell Investments Group Ltd. now owns 2,282 shares of the company’s stock valued at $69,000 after acquiring an additional 828 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Rapport Therapeutics by 64.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock valued at $70,000 after acquiring an additional 905 shares during the period. KBC Group NV purchased a new position in Rapport Therapeutics during the 1st quarter valued at $30,000. Finally, Meeder Asset Management Inc. bought a new position in Rapport Therapeutics in the 4th quarter valued at $37,000.

Rapport Therapeutics News Summary

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: BTIG Research reiterated its “Buy” rating on Rapport Therapeutics, signaling continued confidence in the company’s long-term potential. BTIG Research Reiterates Buy Rating for Rapport Therapeutics
• Neutral Sentiment: HC Wainwright issued quarterly and long-term earnings estimates, forecasting losses of $1.36 per share in Q3 2026 and $1.54 per share in Q4 2026. The firm expects losses to continue through 2030, with estimates ranging from $4.51 per share in fiscal 2026 to $6.96 per share in fiscal 2030. These projections provide updated expectations but do not represent a change in the company’s operating results.
• Negative Sentiment: Wall Street Zen downgraded Rapport Therapeutics to “Sell,” adding fresh analyst pressure to the stock and likely contributing to the weaker trading tone. Rapport Therapeutics Downgraded by Wall Street Zen to Sell
• Negative Sentiment: HC Wainwright’s fiscal 2026 loss estimate of $4.51 per share is worse than the current consensus estimate of a $3.67 per-share loss. The projected losses through 2030 reinforce concerns about continued cash needs and the time required for Rapport’s pipeline to generate revenue or profitability.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.